Clinical Trials Results - National Cancer Institute

In English \| En español

Search


	Clinical Trials Search Results

Page Options

E-Mail This Search

Clinical Trial Questions?

Get Help:

1-800-4-CANCER or

LiveHelp online chat

	Quick Links


	Help Using the NCI Clinical Trials Search Form Educational Materials About Clinical Trials About NCI's Cancer Clinical Trials Registry Dictionary of Cancer Terms NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 80 for your search:

Cancer Type/Condition:  Liver cancer, adult primary
Stage/Subtype:  recurrent adult primary liver cancer
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA182-034, EUDRACT #: 2008-005084-34, NCT00825955

Controlled Trial Comparing Nomogram-based Versus Standard Allocation of Acute Normovolemic Hemodilution (ANH) During Hepatic Resection

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-158, NCT00902343

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M10-963, NCT01009593

Phase I/II Study of Erlotinib Hydrochloride and Cetuximab in Patients With Advanced Gastrointestinal, Head and Neck, Non-Small Cell Lung, or Colorectal Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: VU-VICC-GI-0622, VICC-GI-0622, 6980, NCI-6980, NCT00397384

Low Dose Radiation Therapy as Chemosensitizer in GI/ Ovarian Tumors

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: H-22706, NCT00390182

Evaluation of Single Session Stereotactic Body Radiotherapy

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2005-0445, NCT00492817

Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CTCT 06-11, NCT00493883

Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)

Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: ID02-446, NCT00508443

RAD001 in Advanced Hepatocellular Carcinoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-352, NCT00516165

10.

Phase I/II Study of 3-Dimensional Conformal Radiotherapy, Intra- or Peri-Tumoral Injection of Poly ICLC With Trans-Hepatic Arterial Embolization Followed by Autologous Tumor Cell Vaccine Poly ICLC in Patients With Unresectable, Recurrent, or Metastatic Primary Hepatocellular or Pancreatic Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMDNJ-0120070076, 0120070076, NCT00553683

11.

CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2007-0248, NCT00634751

12.

A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: HGS1012-C1077, NCT00712855

13.

Phase I/II Randomized Study of Sorafenib Tosylate and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N0745, N0745, NCT00867321

14.

Randomized Phase Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PR104-2002, NCT00862082

15.

Hepatic Artery-Directed Internal Radiation Therapy Using Yttrium-90 Microspheres (TheraSphere®) in Patients With Unresectable Hepatocellular Carcinoma (Primary Liver Cancer)

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PCI-IRB-0611014, PCI-IRB-000656, PCI-IRB-000871, NCI-V02-1701, NCT00039078

16.

Phase II Study of Intrahepatic Arterial Infusion of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion in Patients With Unresectable Primary or Metastatic Liver Cancer

Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-04-C-0273, NCI-6332, DELCATH-G990039, NCT00096083

17.

Phase II Study of Bevacizumab and Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: JHOC-J0598, JHOC-NA_00001249, NCT00335829

18.

Phase II Study of Hepatic Arterial Infusion Comprising Floxuridine and Dexamethasone in Combination With Systemic Bevacizumab in Patients With Unresectable Primary Hepatic Malignancy

Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: MSKCC-06114, GENENTECH-MSKCC-06114, NCT00410956

19.

Phase II Study of AZD2171 in Patients With Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MGH-05-311, DFCI IRB 05-311, 7147, NCT00427973

20.

Phase II Study of Dasatinib in Patients With Unresectable Advanced Hepatocellular Carcinoma

Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: NCI
Protocol IDs: CCC-PHII-83, 7792, UPCC-UPCI-06-099, PhII-83, 06-099, NCT00459108

21.

Phase II Pilot Study of Irradiated Allogeneic Related Donor Lymphocyte Infusion in Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187

22.

SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: STX 0106, NCT00503867

23.

Phase II Study of Sunitinib Malate and Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 18
Sponsor: NCI
Protocol IDs: RPCI-I-82706, I 82706, NCT00524316

24.

Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GI06-101, NCT00532441

25.

Phase II Study of AZD6244 in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MCC-15260, MCC-07-0973, MCC-15260, 7909, GCRC-2625-ORC, NCT00550719, VU-VICC-GI-0726, 77782

Select All on Page

Help with Results

A Service of the National Cancer Institute